萊斯康製藥 LXRX 深 滬
已收盤 08-08 16:00:00 美东时间
1.08
-0.040
-3.57%
華盛通- 最 高1.15
- 今 開1.11
- 成交量 283.40万股
- 最 低 1.04
- 昨 收 1.12
- 總市值 3.92亿
- 52周最高 2.175
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 0.2836
- 委 比 40.36%
- 總股本 3.63亿
- 歷史最高 22.96
- 量 比 0.86
- 振 幅 9.82%
- 歷史最低 0.2836
- 每 手 1
- 風險率 0.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $1.9
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $1.2 to $1.9.
08-08 06:49
Lexicon Pharmaceuticals Q2 EPS $0.01 Beats $(0.08) Estimate, Sales $28.866M Beat $4.867M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.08) by 112.99 percent. This is a 105.88 percent increase over losses of $(0.17) per
08-06 19:41
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals reported second quarter 2025 financial results, highlighting increased revenues due to licensing agreements, particularly with Novo Nordisk for LX9851. Key milestones include partnership discussions for pilavapadin progressing, completion of IND-enabling studies for LX9851 expected by 2025, and enrollment on track for the SONATA Phase 3 study in HCM. Additionally, Lexicon remains focused on advancing sotagliflozin in heart...
08-06 11:30
A Glimpse of Prothena Corp's Earnings Potential
Prothena Corp (NASDAQ:PRTA) will release its quarterly earnings report on Monda...
08-02 05:05
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lexicon Pharmaceuticals announced that its common stock has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid price met the $1.00 per share requirement for ten consecutive business days. This update was previously disclosed in the Company’s Form 8-K filed on July 28, 2025. Lexicon, a biopharmaceutical company, focuses on pioneering innovative medicines through its Genome5000™ program, targeting diseases like heart fail...
07-31 12:00
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Lexicon Pharmaceuticals announced they will release their second quarter 2025 financial results on August 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET. The webcast and archived version will be available on their website.
07-23 12:00
Lexicon Pharmaceuticals To Present New Data On Diabetic Nerve Pain Burden At ASPN 2025 Conference
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be
07-18 20:02
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Lexicon announced data from a study on diabetic peripheral neuropathic pain (DPNP) patients despite standard treatment, to be presented at the ASPN 2025 meeting. DPNP, a debilitating complication of diabetes affecting millions, often impacts daily life. Lexicon’s investigational drug, pilavapadin, a novel non-opioid treatment targeting AAK1, showed promising results in reducing DNP pain in Phase 2a trials. The company aims to raise awareness of D...
07-18 12:00
